preludedx dcisionrt logo

Welcome to a New Paradigm for DCIS Management

Predicts radiation benefit.

DCISionRT is the only test capable of predicting an individual patient’s benefit from radiation therapy. Using DCISionRT provides you with 10-year Total and Invasive Recurrence Risk after breast conserving surgery as well as surgery with radiation therapy. No other test can do this.

Enables precision medicine.

DCISionRT provides you the information to deliver precision medicine to your patients. Unlike grade, tumor size or patient age, DCISionRT quantifies a woman’s risk based on her DCIS biology. Studies have shown that DCISionRT reclassifies over 50% of patients compared to grade and size[REF CCR]. The future of DCIS management is here with DCISionRT.

Unmatched clinical evidence.

DCISionRT has undergone multiple independent validations, including the landmark SweDCIS randomized clinical trial. The test has the highest dynamic range and most consistent results study to study. Evidence includes over 2000 patients from development through validation. No other DCIS test is supported by published Level 1b clinical evidence.

DCISionRT provides physicians with the first radio-genomics tool to predict radiation therapy benefit.

In an independent clinical validation of DCISionRT in the landmark SweDCIS randomized clinical trial, patients with low Decision Scores no significant invasive risk reduction from radiation therapy after surgery whereas patients with elevated Decision Scores had a 9% reduction in invasive risk (HR 0.24, p=0.012). This study, for the first time, demonstrates a DCIS test that predicts the extent to which patients benefit from radiation therapy.

DCISionRT enables physicians to deliver precision medicine to DCIS patients

Results are shown are for the 196 patients treated with conserving surgery treated patients with clear margins in a multisite study. Total recurrence risks shown are adjusted for year of diagnosis. This was demonstrated in a multisite study of 474 patients1.

1 Bremer T, Whitworth P, Patel R, et al. . A biologic signature for breast ductal carcinoma in situ to predict radiation therapy (RT) benefit and assess recurrence risk. Clin Cancer Res . 2018; doi:10.1158/1078-0432.CCR-18-0842.

Unmatched Clinical Evidence

Hear what physicians are saying about DCISionRT

What information does DCISionRT give me?

Based on the biology of your DCIS, the DCISionRT test provides you and your physician the information needed to make a decision whether surgery alone or surgery with radiation therapy is appropriate.

Case Studies

The DCISionRT® test indicates your individual risk of recurrence and expected benefit from radiation therapy.

Example 1

Age: 51 years  |  DCIS Grade: Intermediate (Grade 2)  |  DCIS size: 30mm

Before DCISionRT

Risk Assessment
Traditional Clinpath Features

TREATMENT PLAN:
Surgery with radiation therapy

TREATMENT RATIONALE:
Radiation therapy after breast conserving surgery is recommended based on age, grade and size.

After DCISionRT

Risk Assessment

TREATMENT PLAN:
Breast conserving surgery

TREATMENT RATIONALE:
Because the patient has a Low DCISionRT score, the Physician and patient decide to defer radiation therapy and elect breast conserving surgery.

Example 2

Age: 45 years  |  DCIS Grade: Low (Grade 1)  |  DCIS size: 10mm

Before DCISionRT

Risk Assessment
Traditional Clinpath Features

TREATMENT PLAN:
Breast conserving surgery

TREATMENT RATIONALE:
Traditional risk assessment using clinicopathologic features indicates patient could be considered “low risk” and therefore, the patient and physician elect to forego radiation therapy.

After DCISionRT

Risk Assessment

TREATMENT PLAN:
Surgery with radiation therapy

TREATMENT RATIONALE:
New information from DCISionRT indicates the patient is at Elevated Risk if treated with surgery alone. The patient and physician decide to use radiation therapy-–despite traditionally low risk clinicopathalogic features—due to the large risk reduction from radiation therapy.

Ordering Information

  • Female, age 30 – 85
  • Diagnosed with ductal carcinoma in situ (DCIS) of the breast
  • Treated with breast conserving surgery or had a core biopsy
    • Max tissue sample size for surgery – 60mm (6.0 cm)
    • Max tissue sample size for biopsy – 10mm (1.0cm)
  • Minimum tissue required is 1mm of DCIS or 2 ducts with DCIS
  • Any nuclear grade is acceptable: Grade 1 (low), Grade 2 (intermediate) or Grade 3 (high)
  • ER+, ER-, PR+, PR- patients are acceptable
  • Fill out a DCISionRT test requisition form
  • Fax the following information to PreludeDx Customer Care at 1.888.909.3247
    • Completed test requisition form
    • Pathology report
    • Medical/physician notes
    • Insurance card (front and back)
  • Customer Care will request the tissue specimen as indicated on the test requisition
  • PreludeDx currently accepts all insurance plans
  • DCISIonRT list price is $5,995 (PLA Code 0295U)
  • Financial assistance may be available for patients meeting certain requirements
  • Contact our Patient Care Team at 888.211.3247 or email billing@preludedx.com for more information.
  • For initial first-time orders, please allow additional 1-2 days for pathology to arrive at our location.
  • DCISionRT results are typically available within 3-5 days from receiving the tissue specimen
  • Results will be provided via fax, encrypted email or physician portal
DCISionRT gives patients:

  1. Their overall score (continuous risk score and low vs elevated category)
  2. Their rate of recurrence over 10-years
  3. Their benefit of radiation

Contact Customer Care

Phone: 1.888.211.3247 or Email: customercare@preludedx.com